FindTrial
Sign In

CMB305

BIOLOGICAL2 trials

Sponsors

Immune Design, a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA)

Conditions

LiposarcomaLocally Advanced SarcomaMelanomaMetastatic SarcomaMyxoid/Round Cell LiposarcomaNon-small Cell Lung CancerOvarian CancerRecurrent Adult Soft Tissue Sarcoma

Phase 1

Phase 1b Safety Study of CMB305 in Patients With Locally Advanced, Relapsed, or Metastatic Cancer Expressing NY-ESO-1
TerminatedNCT02387125
Immune Design, a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA)Melanoma, Non-small Cell Lung Cancer, Ovarian Cancer +1
Start: 2015-02-28End: 2019-03-29Updated: 2020-07-01

Phase 2

Study to Compare the Safety and Efficacy of CMB305 With Atezolizumab to Atezolizumab Alone in Participants With Sarcoma (IMDZ-C232/V943A-002)
TerminatedNCT02609984
Immune Design, a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA)Liposarcoma, Locally Advanced Sarcoma, Metastatic Sarcoma +4
Start: 2015-04-29End: 2019-02-06Updated: 2020-07-07

Related Papers

Interim results of a real-world observational study of eribulin in soft tissue sarcoma including rare subtypes
Japanese Journal of Clinical Oncology2019-06-1224 citations
A phase II randomized study of CMB305 and atezolizumab versus atezolizumab in NY-ESO-1<sup>+</sup> soft tissue sarcoma: Analysis of immunogenicity, tumor control, and patient survival.
Journal of Clinical Oncology2019-05-2012 citations
Immune response, safety, and overall survival of NY-ESO-1+ soft tissue sarcoma patients treated with CMB305 therapy
Annals of Oncology2018-10-011 citations
Immune response, safety, and survival impact from CMB305 in NY-ESO-1+ recurrent soft tissue sarcomas (STS).
Journal of Clinical Oncology2017-05-2020 citations